Literature DB >> 8640793

Double knockout of the ALL-1 gene blocks hematopoietic differentiation in vitro.

V Fidanza1, P Melotti, T Yano, T Nakamura, A Bradley, E Canaani, B Calabretta, C M Croce.   

Abstract

The ALL-1 gene is involved in translocations with many partner genes in different types of the acute leukemias, but it is not clear whether it acts as an oncogene or whether the fusion proteins resulting from the translocations have dominant negative effects. To distinguish between these two possibilities, we analyzed the ability of wild-type AB2.1 embryonal stem (ES) cells and of single or double ALL-1 gene knockout cells derived from them to differentiate along hematopoietic lineages after withdrawal of leukemia inhibitory factor, using in vitro colony formation assays. All-1 double knockout ES cells formed a significantly greater number of colonies with faster kinetics than wild-type and ALL-1 single knockout ES cells. Parental ES cells formed lineage-restricted colonies, whereas single and double knockout ES cells developed, at high frequency, immature and/or "biphenotypic" colonies, mimicking the aberrant hematopoiesis typical of leukemic patients. These data are consistent with the possibility that loss of function of the ALL-1 gene is important in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640793

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 2.  Roles of a trithorax group gene, MLL, in hematopoiesis.

Authors:  Ryoichi Ono; Tetsuya Nosaka; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

3.  Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies.

Authors:  D Vittet; T Buchou; A Schweitzer; E Dejana; P Huber
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

4.  Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins.

Authors:  H T Adler; R Chinery; D Y Wu; S J Kussick; J M Payne; A J Fornace; D C Tkachuk
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

5.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 6.  Challenges and strategies for generating therapeutic patient-specific hemangioblasts and hematopoietic stem cells from human pluripotent stem cells.

Authors:  Ann Peters; Paul W Burridge; Marina V Pryzhkova; Michal A Levine; Tea-Soon Park; Christopher Roxbury; Xuan Yuan; Bruno Péault; Elias T Zambidis
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

7.  SET1, a yeast member of the trithorax family, functions in transcriptional silencing and diverse cellular processes.

Authors:  C Nislow; E Ray; L Pillus
Journal:  Mol Biol Cell       Date:  1997-12       Impact factor: 4.138

Review 8.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Authors:  Emma C Collins; Alexandre Appert; Linda Ariza-McNaughton; Richard Pannell; Yoshihiro Yamada; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 10.  The role of the MLL gene in infant leukemia.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.